Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Report Overview
2023
Base Year
2018-2023
Historical Year
2024-2032
Forecast Year
Dyspnea Market: Competitor Landscape
In July 2023, Lupin Limited , revealed that its Australian subsidiary, Generic Health Pty Ltd, received approval for Tiotropium 18 micrograms powder for inhalation from Therapeutic Goods Administration (TGA). The approved drug can be used in combination with Lupin Haler and is indicated treating long-term bronchospasm along with dyspnea associated with chronic obstructive pulmonary disease (COPD). It has also been found effective in preventing COPD exacerbations. The surge in drug approvals from key regulatory authorities has been a major market trend, expected to boost the market size in the forecast period.
The key features of the dyspnea market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bausch Health
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd
- Ligand Pharmaceuticals Incorporated
- Amneal Pharmaceuticals LLC
- Jazz Pharmaceuticals, Inc.
- Mylan N.V.
- Lupin
- Pfizer Inc.
- Novartis AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma
- Nephron Pharmaceuticals Corporation
- Zydus Cadila
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Dyspnea Market Report Snapshots
Dyspnea Market Regional Analysis
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Key Questions Answered in the Report
The market attained a value of about USD 6.5 billion in 2023 driven by the rising prevalence of respiratory diseases across the 8 major markets.
The market is anticipated to grow at a CAGR of 6.9% during the forecast period, likely to reach a market value of USD 11.8 billion by 2032.
The increasing prevalence of indoor and outdoor pollutants, increased initiatives by the government to spread awareness among people regarding dyspnea and its treatments, increased prevalence of COPD, and increased FDA approvals are major factors contributing to the market demand.
The increasing number of clinical trials examining the efficacy of drugs, leading to growth in drug approvals from essential regulatory bodies is a major market trend. In July 2023, Lupin's Tiotropium 18 micrograms powder received approval from Therapeutic Goods Administration (TGA) to treat long-term bronchospasm along with dyspnea associated with chronic obstructive pulmonary disease (COPD).
The major regions of the market include United States, EU-4, the United Kingdom, Japan, and China. EU-4 is further divided into Germany, France, Italy, and Spain.
Types of treatments in the market include supplemental oxygen therapy and relaxation therapy.
Types of drug classes used for dyspnea treatment are antianxiety, antibiotics, anticholinergic agents, corticosteroids, and others.
The routes of administration include oral and inhalation, among others.
End users in the market include hospitals, specialty clinics, homecare, ambulatory services, and others.
Key players involved in the market are Bausch Health, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Amneal Pharmaceuticals LLC, Jazz Pharmaceuticals, Inc., Mylan N.V., Lupin, Pfizer Inc., Novartis AG, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Nephron Pharmaceuticals Corporation, and Zydus Cadila.
Purchase Full Report
Datasheet
- Selected Sections, One User
- Printing Not Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Single User License
One User
- All Sections, One User
- One Print Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
Five Users
- All Sections, Five Users
- Five Prints Allowed
- Email Delivery in PDF
- Free Limited Customisation
- Post Sales Analyst Support
50% Discount on Next Update
Corporate License
Unlimited Users
- All Sections, Unlimited Users
- Unlimited Prints Allowed
- Email Delivery in PDF + Excel
- Free Limited Customisation
- Post Sales Analyst Support
- 50% Discount on Next Update
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Our Offices
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124